Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stavudine vs Zidovudine in HIV-Infected Children
NCT00000789Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of stavudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Relative safety and tolerance of oral zidovudine versus oral stavudine at 52 weeks. Status: completed.
02
Drugs
stavudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000789.